Purified anti-β-Amyloid, 17-24 Antibody (Previously Covance catalog# SIG-39220)

Pricing & Availability
Clone
4G8 (See other available formats)
Regulatory Status
RUO
Workshop
HCDM listed
Other Names
AAA, ABETA, ABPP, AD1, APPI, CTFgamma, CVAP, PN-II, PN2, Amyloid beta A4 protein, preA4, protease nexin-II, peptidase nexin-II, beta-amyloid peptide, alzheimer disease amyloid protein, cerebral vascular amyloid peptide, APP, Amyloid Precursor Protein
Previously
Signet Catalog# 9220-02
Signet Catalog# 9220-05
Signet Catalog# 9220-10
Covance Catalog# SIG-39220
Isotype
Mouse IgG2b, κ
Ave. Rating
Submit a Review
Product Citations
publications
4G8_Pure_Beta-Amyloid_Ascites_Antibody_1_070218
IHC staining of purified anti-β-Amyloid, 17-24 antibody (clone 4G8) on formalin-fixed paraffin-embedded human Alzheimer's disease brain tissue. Following antigen retrieval using 88% formic acid for 20 minutes at room temperature, the tissue was incubated with 1 µg/ml of the primary antibody for 60 minutes at room temperature. BioLegend´s Ultra-Streptavidin (USA) HRP kit (Multi-Species, DAB, Cat. No. 929901) was used for detection followed by hematoxylin counterstaining, according to the protocol provided. The image was captured with a 40X objective. Scale bar: 50 µm
  • 4G8_Pure_Beta-Amyloid_Ascites_Antibody_1_070218
    IHC staining of purified anti-β-Amyloid, 17-24 antibody (clone 4G8) on formalin-fixed paraffin-embedded human Alzheimer's disease brain tissue. Following antigen retrieval using 88% formic acid for 20 minutes at room temperature, the tissue was incubated with 1 µg/ml of the primary antibody for 60 minutes at room temperature. BioLegend´s Ultra-Streptavidin (USA) HRP kit (Multi-Species, DAB, Cat. No. 929901) was used for detection followed by hematoxylin counterstaining, according to the protocol provided. The image was captured with a 40X objective. Scale bar: 50 µm
  • 4G8_Pure_Beta-Amyloid_Ascites_Antibody_2_070218
    IHC staining of purified anti-β-Amyloid, 17-24 antibody (clone 4G8) on formalin-fixed paraffin-embedded human Alzheimer's disease brain tissue. Following antigen retrieval using 88% formic acid for 20 minutes at room temperature, the tissue was incubated with 1 µg/ml of the primary antibody for 60 minutes at room temperature. BioLegend´s Ultra-Streptavidin (USA) HRP kit (Multi-Species, DAB, Cat. No. 929901) was used for detection followed by hematoxylin counterstaining, according to the protocol provided. The image was captured with a 40X objective. Scale bar: 50 µm
  • 4G8_Pure_Beta-Amyloid_Ascites_Antibody_3_070218
    Direct ELISA of purified anti-β-Amyloid, 17-24 (clone 4G8) antibody binding to the plate-immobilized human Aβ1-40, human Aβ1-42, rodent Aβ1-42 peptides, and recombinant human APP751 protein. ELISA was performed by coating the wells with 100 ng of peptide or recombinant protein. The wells were then incubated with the primary antibody at 37°C for 45 minutes, followed by incubation with HRP labeled goat anti-mouse IgG secondary antibody. TMB (3, 3', 5, 5' tetramethylbenzidine, Cat. No. 421501) was used as the detection system.
Compare all formats
Cat # Size Price Save
800712 25 µL ¥22,050
800701 200 µL ¥109,200
800702 500 µL ¥213,360
800703 1 mL ¥350,910
Description

Alzheimer’s disease is characterized by the accumulation of aggregated Aβ peptides in senile plaques and vascular deposits. Aβ peptides are derived from amyloid precursor proteins (APP) through sequential proteolytic cleavage of APP by β-secretases and γ-secretases generating diverse Aβ species. Aβ can aggregate to form soluble oligomeric species and insoluble fibrillar or amorphous assemblies. Some forms of the aggregated peptides are toxic to neurons.

Product Details
Technical data sheet

Product Details

Verified Reactivity
Human, Mouse
Antibody Type
Monoclonal
Host Species
Mouse
Formulation
Phosphate-buffered solution (no preservatives or carrier proteins).
Preparation
The antibody was purified by affinity chromatography.
Concentration
1 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C. Please note the storage condition for this antibody has been changed from -20°C to between 2°C and 8°C. You can also check your vial or your CoA to find the most accurate storage condition for this antibody.
Application

IHC-P - Quality tested
Direct ELISA - Verified
IHC-F, ICC, IP - Reported in the literature, not verified in house

Recommended Usage

Each lot of this antibody is quality control tested by formalin-fixed paraffin-embedded immunohistochemical staining. For immunohistochemistry, a concentration range of 1.0 - 2.0 µg/ml is suggested. For Direct ELISA applications, a concentration range of 0.15 - 0.5 µg/mL is recommended. It is recommended that the reagent be titrated for optimal performance for each application.

Application Notes

This antibody is reactive to amino acid residues 17-24 of ß amyloid. The epitope lies within amino acids 18-22 of ß amyloid (VFFAE). 4G8 ß-amyloid antibody reacts to abnormally processed isoforms, as well as precursor forms.

This antibody clone has been reported for use on IHC of free-floating sections in PBS containing 1% Triton incubated with 0.1 m citrate buffer (4).

Additional reported applications (for the relevant formats) include: immunohistochemical staining on frozen tissue sections (IHC-F) and immunocytochemistry (ICC)

Additional Product Notes

View more applications data for this product in our Scientific Poster Library.

Application References

(PubMed link indicates BioLegend citation)
  1. Poduslo JF, et al. 2004. Biochem. 43:6064. (IHC-F) PubMed
  2. Forny-Germano L, et al. 2014. J Neurosci. 34:13629. (IHC-Other) PubMed
  3. Vallino Costassa E, et al. 2016. J Alzheimers Dis. 51: 875-87. (IHC-P) PubMed
  4. Chen X, et al. 2013. Neurobiol Aging. 34:2370. (ICC) PubMed
  5. Hatami A, et al. 2016. J Alzheimers Dis. 50:517. (IHC-P) PubMed
  6. Kawarabayashi T, et al. 2001. J Neurosci 21:372 (IP)
  7. Fonte V, et al. 2002. PNAS. 110:4853 (IP)
Product Citations
  1. Illouz T, et al. 2021. Vaccine. 39:4817. PubMed
  2. Jovic M, et al. 2019. PLoS One. 14:e0216726. PubMed
  3. Crivelli SM, et al. 2021. Alzheimers Res Ther. 13:45. PubMed
  4. Kretner B, et al. 2016. EMBO Mol Med. 10.15252/emmm.201505952. PubMed
  5. Lutzenberger M, et al. 2015. PLoS One. 10: 0134228. PubMed
  6. Forny-Germano L, et al. 2014. J Neurosci. 34:13629-13643. PubMed
  7. Doustar J, et al. 2020. Aging Cell. :e13246. PubMed
  8. Finke JM, et al. 2017. Biochim Biophys Acta. 1861:2228. PubMed
  9. Smith AM, et al. 2021. Acta Neuropathol. Online ahead of print. PubMed
  10. Cao KJ, et al. 2021. Transl Vis Sci Technol. 10:5. PubMed
  11. A Kimura, S Hata, T Suzuki 2016. J Biol Chem. 291: 24041 - 24053. PubMed
  12. Keable A, et al. 2016. Biochim Biophys Acta. 1862:1037-1046. PubMed
  13. Sun F, et al. 2020. Front Cell Dev Biol. 8:565020. PubMed
  14. Iacono D, et al. 2020. J Neuropathol Exp Neurol. 79:144. PubMed
  15. Jäkel L, et al. 2019. Acta Neuropathol Commun. 7:141. PubMed
  16. Braak H, et al. 2018. Cereb Cortex. 28:3372. PubMed
  17. Lisa Dolfe et al. 2018. Journal of Alzheimer's disease reports. 2(1):27-39 . PubMed
  18. González C, et al. 2018. Mol Psychiatry. 23:2363. PubMed
  19. Wu C, et al. 2020. Med Sci Sports Exerc. 52:1456. PubMed
  20. Chiang ACA, et al. 2018. Am J Pathol. 188:739. PubMed
  21. Zhang L, et al. 2018. Neurobiol Dis. 114:01:00. PubMed
  22. Trambauer J, et al. 2020. EMBO Rep. 21:e47996. PubMed
  23. Elmer BM, et al. 2019. PLoS One. 14:e0226245. PubMed
  24. Kim E, et al. 2021. Biomolecules. 11:. PubMed
  25. Wang C, et al. 2022. Front Pharmacol. 12:763866. PubMed
  26. Guo X, et al. 2020. Aging Dis. 1.446527778. PubMed
  27. Rush T, et al. 2018. J Neurosci. 38:10349. PubMed
  28. Osborne C, et al. 2018. J Cell Sci. 131:. PubMed
  29. Uhlmann RE, et al. 2020. Nat Neurosci. 23:1580. PubMed
  30. Liu L, et al. 2017. Sci Rep. 7:40467. PubMed
  31. Mo D, et al. 2020. Cells. 9:00. PubMed
  32. Colvin BA, et al. 2017. J Neurochem. 143:736. PubMed
  33. Guan Z, et al. 2020. Front Cell Neurosci. 0.763888889. PubMed
  34. Zhang H, et al. 2021. Protein Cell. 12:695. PubMed
  35. Benbow SJ, et al. 2020. Hum Mol Genet. 495:29. PubMed
  36. Fenyi A, et al. 2021. Cells. 10:. PubMed
  37. Nuvolone M, et al. 2017. PLoS One. 12:e0171923. PubMed
  38. Romani M, et al. 2021. Cell Reports. 34(3):108660. PubMed
  39. Wang ZH, et al. 2021. Prog Neurobiol. 202:102032. PubMed
  40. Yamamoto S, et al. 2021. npj Science of Food. 5(1):1. PubMed
  41. Shi H, et al. 2020. Acta Neuropathol. 139:813. PubMed
  42. Furukawa F, et al. 2018. Prion. 12:315. PubMed
  43. Kim E, et al. 2021. Sci Rep. 11:12419. PubMed
  44. Mol MO, et al. 2021. Neurol Genet. 7:e596. PubMed
  45. Sherman M, et al. 2016. J Neurosci. 36: 9647 - 9658. PubMed
  46. Natunen T, et al. 2020. Mol Neurodegener. 0.670833333. PubMed
  47. Wu Y, et al. 2019. Nat Commun. 10:58. PubMed
  48. Lauretti E, et al. 2017. Ann Clin Transl Neurol. 4:564. PubMed
  49. Puzzo D, et al. 2020. Journal of Clinical Investigation. 130(9):4831-4844. PubMed
  50. Lee JH, et al. 2022. Nat Neurosci. 25:688. PubMed
  51. Cacciottolo M, et al. 2017. Transl Psychiatry. 7:e1022. PubMed
  52. Lian H, et al. 2016. J Neurosci. 36: 577 - 589. PubMed
  53. Garcia–Esparcia P, et al. 2017. Front Neurol. 8:89. PubMed
  54. Eimer WA et al. 2018. Neuron. 99(1):56-63 . PubMed
  55. Liu XC, et al. 2021. Front Aging Neurosci. 13:639318. PubMed
  56. Liu S, et al. 2022. J Neuroinflammation. 19:35. PubMed
  57. Shimada H, et al. 2022. Cell Rep Methods. 2:100289. PubMed
  58. Zhang J, et al. 2019. Aging Cell. 18:e12978. PubMed
  59. Li JG, et al. 2019. Mol Psychiatry. 10.1038/s41380-019-0364-x. PubMed
  60. Plá V, et al. 2017. Front Mol Neurosci. 10:202. PubMed
  61. Grant MKO, et al. 2019. PLoS One. 14:e0212815. PubMed
  62. Lu J, et al. 2021. EMBO Rep. 22:e52013. PubMed
  63. Kaneshiro N, et al. 2022. iScience. 25:103869. PubMed
  64. Fassler M, et al. 2021. J Neuroinflammation. 18:19. PubMed
  65. Iacono D, et al. 2018. Parkinsonism Relat Disord. 58:63. PubMed
  66. Zhao P, et al. 2019. Front Behav Neurosci. 13:138. PubMed
  67. Van Skike CE, et al. 2021. J Neurosci. 41:4305. PubMed
  68. Podracky CJ, et al. 2021. Nat Chem Biol. 17:317. PubMed
  69. Fixemer S, et al. 2022. Acta Neuropathol Commun. 10:36. PubMed
  70. Sau-Yeen Loke, Peter Tsun-Hon Wong, Wei-Yi Ong 2017. Neurochem Int. 102:33-56. PubMed
  71. Shi H, et al. 2020. Acta Neuropathol Commun. 0.473611111. PubMed
  72. Prpar Mihevc S, et al. 2019. Front Neurosci. 13:604. PubMed
  73. Carrillo-Jiménez A, et al. 2019. Cell Rep. 29:697. PubMed
  74. Zhu B, et al. 2022. Chem Sci. 13:8104. PubMed
  75. Kim S, et al. 2020. Int J Mol Sci. 21:00. PubMed
  76. Jäkel L, et al. 2020. Mol Neurobiol. 57:2131. PubMed
  77. Meilandt WJ, et al. 2020. J Neurosci. 40:1956. PubMed
  78. Harper MM, et al. 2019. Invest Ophthalmol Vis Sci. 60:2716. PubMed
  79. Kim S, et al. 2019. Int J Mol Sci. 20. PubMed
  80. Libard S, et al. 2021. J Alzheimers Dis. 80:1003. PubMed
  81. Espinoza S, et al. 2022. Cells. 11:. PubMed
  82. Prpar Mihevc S, et al. 2020. Front Vet Sci. 7:573155. PubMed
  83. Ezpeleta J, et al. 2019. Nat Commun. 10:3442. PubMed
  84. Pires G, et al. 2019. Acta Neuropathol Commun. 0.427083333. PubMed
  85. Wang ZH, et al. 2019. Cell Rep. 28:655. PubMed
  86. Lee KH, et al. 2017. Yonsei Med J. 58:1055. PubMed
  87. Carranza-Naval MJ, et al. 2022. Front Aging Neurosci. 13:741923. PubMed
  88. Xu G, et al. 2020. Acta Neuropathol Commun. 8:43. PubMed
  89. Luo R, et al. 2020. Autophagy. 16:52. PubMed
  90. Song JX, et al. 2020. Aging Cell. 19:e13069. PubMed
  91. Li JG, et al. 2020. Mol Neurodegener. 15:01. PubMed
  92. Wang B, et al. 2017. Mol Psychiatry. 22:990. PubMed
  93. Jonson M, et al. 2018. Cell Chem Biol. 25:595. PubMed
  94. West E, et al. 2017. J Cell Sci. 130:3050. PubMed
  95. Rayaprolu S, et al. 2020. Mol Neurodegener. 15:28. PubMed
  96. Rivera I, et al. 2018. Cell Stress Chaperones. 23:269. PubMed
  97. Catania M, et al. 2022. Mol Psychiatry. :. PubMed
  98. Lo Cascio F, et al. 2020. J Biol Chem. 295:14807. PubMed
  99. Wang W et al. 2019. EBioMedicine. 42:174-187 . PubMed
RRID
AB_2734548 (BioLegend Cat. No. 800712)
AB_2564633 (BioLegend Cat. No. 800701)
AB_2564634 (BioLegend Cat. No. 800702)
AB_662812 (BioLegend Cat. No. 800703)

Antigen Details

Structure
Amyloid precursor protein is a 770 amino acid protein with a molecular mass of ~100 kD. According to the UniProtKB database, APP (ID# P05067) has 11 isoforms (34 to ~90 kD) and the 770 form has been designated as the canonical form. Isoform APP695 is the predominant form expressed in neuronal tissue. Isoforms APP751 and APP770 are widely expressed in non-neuronal cells. Isoform APP751 is the most abundant form in T-lymphocytes. Aβ denotes peptides of 36-43 amino acids generated from cleavage of APP by secretases. Aβ has an apparent molecular mass of about 4 kD.
Distribution

Tissue distribution: Primarily nervous system, but also adipose tissue, intestine, and muscle.
Cellular distribution: Cytosol, endosomes, nucleus, plasma membrane, extracellular, and golgi apparatus.

Function
The normal function of Aβ is not well understood. Several potential physiological roles have been proposed, including: activation of kinase enzymes; protection against oxidative stress; regulation of cholesterol transport; transcription factor, and as an anti-microbial agent.
Biology Area
Cell Biology, Neurodegeneration, Neuroscience, Protein Misfolding and Aggregation
Molecular Family
APP/β-Amyloid
Antigen References
  1. Kumar A, et al. 2015. Pharmacol Rep. 67(2):195.
  2. Sadigh-Eteghad S, et al. 2015. Med Princ Pract. 24(1):1
  3. Hampel H, et al. 2015. Expert Rev Neruother. 15(1):83.
  4. Puig KL, et al. 2012. Exp Gerontol. 48(7): 608.
  5. Selkoe DJ, et al. 2016. EMBO Mol Med. 8(6):595.
  6. Walsh DM, et al.  2007. J Neurochem. 101(5):1172.
Gene ID
351 View all products for this Gene ID
UniProt
View information about beta-Amyloid, 17-24 on UniProt.org

Related FAQs

There are no FAQs for this product.
Go To Top Version: 6    Revision Date: 12/16/2021

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

 

*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/ordering#license). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

 

BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

  • Anti-β-Amyloid, 17-24

  • Biotin anti-β-Amyloid, 17-24

  • Purified anti-β-Amyloid, 17-24

  • Alexa Fluor® 488 anti-β-Amyloid, 17-24

  • Alexa Fluor® 647 anti-β-Amyloid, 17-24

  • Alexa Fluor® 594 anti-β-Amyloid, 17-24

  • HRP anti-β-Amyloid, 17-24

  • Spark YG™ 570 anti-β-Amyloid, 17-24

ProductsHere

Login / Register
Remember me
Forgot your password? Reset password?
Create an Account